Colorectal Cancer

The European Medicines Agency’s CHMP has issued a positive opinion for encorafenib plus cetuximab and mFOLFOX6 in first-line BRAF V600E–mutant mCRC.

Marwan G. Fakih, MD, outlines situations when ctDNA and tissue NGS agree, when they diverge, and scenarios that should prompt repeat liquid biopsy testing.

CHMP recommended trastuzumab deruxtecan for HER2-positive (IHC 3+) metastatic solid tumors, marking the first tumor-agnostic ADC opinion in the EU.

The FDA approved Dato-DXd for PD-1/PD-L1–ineligible triple-negative breast cancer, granted priority review to sevabertinib in HER2-mutant NSCLC, and more.

The FDA has granted fast track designation to suplexa in MSI-H CRC.

Polls highlighted key abstracts of interest from the upcoming ASCO Annual Meeting.

Pelareorep plus bevacizumab and FOLFIRI showed a 33% response rate and 19.5-month median response duration in RAS-mutant MSS CRC.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HER2+ breast cancer, pancreatic cancer, colorectal cancer, and melanoma.

Ozekibart plus FOLFIRI produced ORRs that exceed historical benchmarks for standard later-line CRC regimens.

Translational analyses from NEOPRISM-CRC also link ctDNA clearance/kinetics and TCR clonality with pCRs, supporting biomarker-guided treatment selection.

Colton Jones, MD, and Joel Saltzman, MD, discuss the potential role of GLP-1 receptor agonists in CRC prevention based on retrospective data.

Experts highlight ctDNA-guided strategies, ADCs, and targeted therapies shaping CRC research in the first quarter of 2026.

The FDA grants full approval to brexu-cel in mantle cell lymphoma, grants priority review to a lirafugratinib NDA in FGFR2+ pretreated cholangiocarcinoma, and more.

Research found that adjuvant immunotherapy plus chemotherapy in stage 3 colon cancer was associated with a reduction in recurrence vs chemotherapy alone.

Jeremy Kortmansky, MD, discusses early-onset CRC, the importance of molecular profiling, and emerging therapeutic targets in this clinician-focused FAQ.

We recap the top regulatory decisions of March in GI malignancies.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, colorectal cancer, breast cancer, chronic myeloid leukemia, and multiple myeloma.

The top 5 OncLive TV videos of the week cover insights in colorectal cancer, breast cancer, bladder cancer, and more

Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study evaluating the MET-directed ADC Temab-A vs SOC active surveillance in postadjuvant, ctDNA-positive CRC.

The FDA approved a teclistamab combination in relapsed/refractory myeloma, Pylarify TruVu for PSMA-PET imaging in prostate cancer, and more.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.

John L. Marshall, MD, and Christopher Lieu, MD, comment on the rising incidence of early-onset colorectal cancer (CRC) during CRC Awareness Month.

Shubham Pant, MD, MBBS, discusses the importance of early biomarker testing in mCRC to guide targeted therapy selection and ensure full clinical benefit.

The FDA has granted accelerated approval to zongertinib in HER2 TKD–mutated NSCLC, full approval to an encorafenib combination in BRAF V600E+ mCRC, and more.

February brought key GI cancer updates: FDA approvals in BRAF+ mCRC and pancreatic cancer, plus new fast track and orphan designations.